B A C K G R O U N D
Renal denervation (RDN) is an invasive technique to disrupt nerves surrounding the renal artery that play an important role in hypertension [1] . This can be achieved by various methods, including radiofrequency energy, ultrasound or the injection of ethanol. The main indication for performing RDN is difficultto-control hypertension. However, a consistent blood pressure (BP)-lowering effect of RDN has not yet been robustly demonstrated when compared with standard (pharmacological) treatment or sham procedure [2] [3] [4] [5] [6] [7] . This emphasizes the importance of carefully studying the safety of this intervention. The invasive nature of RDN and the use of contrast agents raise concerns about potential kidney damage [8] . As a consequence, patients with impaired renal function are often excluded from RDN studies [3-5, 7, 9] .
Given these considerations, we were interested in the renal safety of catheter-based RDN. Recently, a meta-analysis based on seven randomized controlled trials (RCTs) showed that RDN does not affect estimated glomerular filtration rate (eGFR) when compared with control patients [10] . To date, many studies investigating the effects of RDN have been published, far exceeding the number of RCTs [11] . Our specific interest in safety allows a more liberal approach for study inclusion. Therefore, we performed a systematic search to identify all studies reporting on the effect of catheter-based RDN on renal Nephrol Dial Transplant (2017) 32: 1440-1447 doi: 10.1093/ndt/gfx088 Advance Access publication 8 July 2017 function as a reflection of renal safety. The inclusion of observational follow-up studies, which are often larger and with longer follow-up duration, is of additional value when studying unintended effects, compared with focusing only on RCTs [12] . Our primary objective was to quantify the effect on eGFR, because it is a reliable and frequently measured parameter of renal function. Other objectives were quantifying the effect on serum creatinine, serum cystatin C levels and urinary protein concentrations, the latter being a sign of renal injury.
M A T E R I A L S A N D M E T H O D S

Data sources and search strategy
The Embase and MEDLINE databases were searched for RDN studies published between January 2009 and May 2016 by use of the search terms 'renal' AND 'denervation'. This search was previously performed by Howard et al. [11] and contained publications from January 2009 to December 2014. They included all RDN studies that recorded baseline and follow-up BP measurements. We considered it not very likely that authors reported renal function after RDN but failed to quote BP. We updated this search to May 2016. References from relevant studies were screened for supplementary articles. The updated search was performed by one author (M.F.S.) in consultation with a second author (M.L.B.). The search output was extracted from the databases by use of EndNote X7 (Thomson Reuters). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement served as a guideline for the current report (Supplementary Table S1 ) [13] .
Eligibility criteria
We included any RCT, non-randomized comparative (NRC) study or cohort study that provided information on the effects of catheter-based RDN on renal endpoints in adult patients after a follow-up of at least 1 month (to avoid inclusion of contrast-induced acute renal injury) [14] . There were no restrictions on denervation method or indication for RDN. Studies reporting in English on populations that fulfilled the above criteria were included in the review. Endpoints of interest were clinical renal parameters reflecting renal function or injury: eGFR based on cystatin C or creatinine [by Modification of Diet in Renal Disease (MDRD), Cockcroft-Gault or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulas), serum creatinine or cystatin C levels, urine albumin and/or protein concentration, urine albumin:creatinine ratio (ACR) or protein:creatinine ratio [15] [16] [17] .
Screening and data extraction
Titles and abstracts were screened by one author (M.F.S.) who discarded studies that were not pertinent to the topic, again in consultation with a second author (M.L.B.). Case reports, conference abstracts, reviews, editorials and letters were excluded from analyses. Duplicates were also excluded. Remaining articles were checked by full-text evaluation for eligibility according to the criteria by one of the authors (M.F.S., M.M.). In case of multiple publications from one trial (overlapping populations), only the study that reported on the largest population and/or the longest follow-up was included. Study characteristics, patient characteristics, procedural details, change in BP and renal outcomes were extracted by one of the authors (M.F.S., M.M.).
Assessment of risk of bias and applicability
Key biases to consider for our review were attrition bias (non-random occurrence of incomplete outcome data), publication bias (publication or non-publication of research findings, depending on the nature and direction of results) and outcome reporting bias (selective reporting of some outcomes but not others, depending on the nature and direction of results) [18] . We used various methods to obtain an impression of the potential risk of bias: study and baseline patient characteristics from studies that met inclusion criteria but did not report a change in renal function were compared with characteristics of the included studies. We composed a short quality assessment tool containing three questions to assess attrition bias, selection bias (the method of patient selection for the study influences the outcome) and applicability on the cohort level (n ¼ 71) (see Supplementary Table S2 ). Questions were based on existing quality assessment scales, adjusted to the current review [18] . The reference criteria for applicability are based on the inclusion and exclusion criteria of the first RDN articles [3, 4, 19] . Scoring was performed by two authors independently (M.F.S., M.M.). A funnel plot was generated to assess asymmetry (among other causes, a possible indication of reporting/publication bias), followed by an Egger's test to investigate the significance of asymmetry and a 'trim and fill' test if applicable, a statistical technique to correct asymmetry and recalculate the effect size based on this new balance [20, 21] .
Statistical analyses
The change in clinical renal parameters based on paired analyses (i.e. change within the patient) from each cohort was used for the meta-analysis. When available, the mean difference with corresponding standard deviation (SD), standard error of the mean (SEM) or confidence interval (CI) was directly extracted from the article. When only mean values (SD) at baseline and during follow-up were reported, an estimate of the correlation in renal function within individuals was needed to calculate the correct SE of the change in mean renal function. To obtain an estimate of the height of this correlation, we used baseline values, follow-up values and the P-value for change to calculate the mean difference with SD and SEM based on paired and unpaired analyses. Then, the covariance between baseline and follow-up was determined by use of the formula rho ¼
. When no information on a paired test was available, SEM was calculated by imputing the median covariance.
Mean values and SDs of two cohorts from one study were pooled when baseline or follow-up values were presented per cohort while the other was shown as an overall value (pooled mean ¼
). Serum creatinine presented in mg/dL was converted to mmol/L (multiplied by 88.4) and SEM was converted to SD (SD ¼ ffiffiffi n p ÃSEM). Mean values (SD) were estimated from median values with interquartile range (IQR) if necessary [22] .
The directly extracted or calculated change in renal outcomes and its corresponding SE were then meta-analysed across studies with random effects models using inverse variance weighting (DerSimonian and Laird). Results were presented as pooled estimates together with 95% CIs. The meta-analytical method was similar for all renal function parameters.
Univariable random effects meta-regression analyses with study-level characteristics were performed to explain betweenstudy variation, including the relation between eGFR and follow-up time. With respect to risk of bias, the total score of the first and second question was used for the meta-regression analysis. Cohorts were considered to have a high risk of bias when the total percentage of low risk was 0%.
The analyses were performed with R statistical software (version 3.0.3; R Project for Statistical Computing, Vienna, Austria, http://R-project.org), metafor-package and SPSS Statistics for Windows (version 21.0; IBM, Armonk, NY, USA). Descriptive data are presented as mean 6 SD unless stated otherwise. P-values <0.05 were considered statistically significant.
R E S U L T S
Study selection
The 148 citations found by Howard et al. [11] were combined for title and abstract screening with 512 citations found by the updated search after removing duplicates (Figure 1 ). From these 660 citations, 522 were excluded for various reasons, listed in Figure 1 . After full-text evaluation, another 80 reports were excluded because information on change in renal function was not provided or because study populations appeared to be largely overlapping (listed in Supplementary Table S3 ). Sixty-six reports were eligible for analysis of renal outcomes, of which 52 could be included in the quantitative analysis and 14 in the qualitative review.
Study and patient characteristics
From the 52 studies that were included in quantitative analyses, 38 were cohorts, 4 were NRC studies and 10 were RCTs (Supplementary Table S4 ). These studies reported data on 56 RDN cohorts (some articles reported on more than one cohort) consisting of 2550 patients in total with a cumulative follow-up of 22 941 months (mean 9 months, median 6 months). The main indication for performing RDN was hypertension (82.7% of RDN studies) and radiofrequency ablation was the predominant RDN method.
Five studies reported incorrect units or apparently confused SEM with SD, which were adjusted or (partially) excluded [23] [24] [25] [26] [27] . Another five studies had one or more values that needed to be transformed or calculated (pooling of subgroups or transformation from median to mean values with SD) [28] [29] [30] [31] [32] .
Quantitative analysis of eGFR
The mean values of the baseline patient characteristics from each cohort were weighted and pooled ( Follow-up parameters are also shown in Table 1 .
Forty-eight RDN cohorts were eligible for pooling the change in eGFR from 2381 patients. The pooled mean change in eGFR is 0.64 mL/min/1.73 m 2 (95% CI À0.47 to 1.76, P ¼ 0.26) after a mean follow-up time of 9 months after RDN ( Figure 2 ). For this calculation we needed to impute the median covariance for 20 cohorts. When imputation was not performed, the pooled mean change in eGFR (of mainly unpaired data) was 0.07 mL/min/1.73 m 2 (95% CI À1.16 to 1.31, P ¼ 0.91, I
2 ¼ 4.19%). The funnel plot of the meta-analysis (Supplementary Figure  S1) , in which studies instead of cohorts are plotted, shows a significant asymmetry (P ¼ 0.01 by Egger's test); studies are Table 2 ). This suggests that younger age, lower BMI and greater reduction of antihypertensive drugs after RDN have a positive effect on the course of eGFR. Longer follow-up leads to a decline in eGFR.
A sensitivity analysis by only meta-analysing data from RCTs (n ¼ 11 cohorts) showed a pooled mean change of À0.43 mL/min/1.73 m 2 (95% CI À2.71 to 1.85, P ¼ 0.71, I 2 ¼ 84%), an estimate substantially overlapping with the pooled estimate from all studies.
Quantitative analyses of change in other clinical renal parameters
Due to the small number of included studies for the analysis of serum cystatin C levels and ACR, no calculation of paired analyses was possible. Therefore, baseline and follow-up values were considered independent, which affects the precision of the estimates. Data on change in serum creatinine levels were available for 33 RDN cohorts, representing 1615 patients. The median covariance needed to be imputed for 20 cohorts. As shown in Supplementary Figure S2a , the effect estimate was À0.30 lmol/L (95% CI À2.41 to 1.81, P ¼ 0.78). A funnel plot of the analysis, with eight imputed studies by the 'trim and fill' method because of asymmetry, is presented in Supplementary Figure S2b .
Serum cystatin C levels before and after RDN were available from four cohorts representing 448 patients and included Symplicity HTN3 2014 6M (Supplementary Figure S3) . The pooled mean change was 0.07 mg/dL (95% CI 0.03 to 0.10, P < 0.001).
Five studies representing 138 patients provided information on change in ACR (Supplementary Figure S4) . The pooled mean change was À63.57 mg/g (95% CI À100.77 to À26.38, P < 0.001).
Qualitative review
Studies describing changes in renal parameters after RDN without showing quantitative estimates were eligible for a qualitative review. These 14 studies (348 patients in 15 cohorts) reported on the effect of RDN on renal parameters (Supplementary Table S5 ); 13 studies reported an overall unchanged renal function and 1 study reported reduced renal function in 27% of patients and improved renal function in 18% of patients [33] . 
Studies with no information on change in renal function
The study and patient characteristics of the RDN cohorts (31 cohorts representing 1653 patients) that did not report on changes in renal function but did meet the other criteria were compared with the included RDN cohorts (data not shown). There seemed to be no major difference between the two sets of studies/cohorts. The most notable differences between studies with no information on change in renal function and studies included in the quantitative analysis were the indication for RDN (100% hypertension versus 83%, respectively), RDN method used (87% radiofrequency versus 96%, respectively) and baseline eGFR (79.5 6 28.1 versus 75.7 6 21.6 mL/min/ 1.73 m 2 , respectively).
Risk of bias assessment
Supplementary Table S6 shows the individual scores of all included cohorts (N ¼ 71). The total percentage of 'low risk' scored per cohort is either 0, 50 or 100. Eighteen cohorts scored 100%, 32 cohorts scored 50% and 21 cohorts scored 0%, which means that these 21 cohorts have the highest risk of bias. Risk of bias was not related to change in eGFR (Table 2) . Applicability based on inclusion and exclusion criteria was good in 31 cohorts. 
D I S C U S S I O N
This meta-analysis of 52 studies representing 2550 patients treated with RDN shows that renal function does not change significantly or in a clinically meaningful way after a mean follow-up of 9.1 67.0 months when examining eGFR or serum creatinine. Serum cystatin C, reported in only four studies, significantly increased after RDN. Furthermore, ACR significantly improved, based on five studies. Findings of a qualitative review based on 14 additional studies are in line with the analyses of eGFR and serum creatinine. Overall, these findings indicate no major changes in eGFR after the procedure, supporting the notion that RDN is safe with respect to subsequent renal function up to at least 9 months after RDN. The effect of RDN on eGFR has been investigated before in 574 patients [10] . The authors restricted the analysis to RCTs. Based on seven trials, the pooled effect size in the treatment arm was À1.48 (95% CI À3.48 to 0.51) 6 months after RDN. These RCTs are also included in the current analysis. However, there are many more RDN studies published in the literature. An important difference between the previous and the current study is that we primarily included single-arm studies and that we did not restrict inclusion to RDN indication or device used. We were able to base our conclusion on considerably increased numbers and diverse sources of patients with a longer follow-up duration. Therefore our pool of studies better reflects real-life clinical practice. Despite these differences, both analyses show a non-significant change in renal function. Our sensitivity analysis, exploring the effect estimate in only RCTs, showed a nonsignificant change in renal function [À0.43 mL/min/1.73 m 2 (95% CI À2.71 to 1.85), P ¼ 0.71]. Interestingly, the I 2 of this subgroup is 84%, where it is 80% in the general analysis, possibly suggesting no effect of study design on the observed change in eGFR.
As expected from the natural course of eGFR, cohorts with an older age at baseline and longer follow-up after RDN showed a decline in renal function. We found an inverse relation between eGFR and the number of prescribed antihypertensive drugs after RDN, suggesting an improvement of renal function when the number of prescribed drugs is reduced. This association could explain why we observed no significant change in renal function instead of an expected decrease over time, particularly in the hypertensive population [34, 35] . However, compliance to medication was not described in the included studies. The positive effect on renal function, independent of BP, is especially expected from diuretic withdrawal and described in the literature [36, 37] . It has also been demonstrated that higher BMI is related to higher serum creatinine levels and that it is a known risk factor for the development of CKD, which is in line with our analysis demonstrating a decline in eGFR in cohorts with the highest average BMI [38] [39] [40] . The exact method of eGFR measurement (MDRD, Cockcroft-Gault or CKD-EPI) is irrelevant in this respect since the change in eGFR is analysed. Despite a clinically relevant mean reduction in BP after RDN, BP change was not related to the change in renal function. This finding is in agreement with earlier reports, in which BP-independent effects of RDN are described [26, 41] .
RDN may also have beneficial effects on renal function. Ott et al. [41] performed a pilot study (included in the present analysis) demonstrating that RDN slows the decline of renal function in patients with CKD stages 3 and 4. In 27 patients the annual decline in renal function changed from À4.8 6 3.8 in the 3 years before RDN to þ1.5 6 10 mL/min/1.73 m 2 in the first year after RDN. A comparable finding was described by Kiuchi et al. [43] (excluded from the present analysis because of an overlapping population); ACR, a measure for glomerular damage, and serum creatinine significantly decreased over the 2-year follow-up after RDN in hypertensive patients with CKD stages 2-4 [42] . Furthermore, in a previously performed study by Ott et al. [43] , the authors observed a reduction in albuminuria 6 months after RDN, parallel to a reduction in office systolic BP. Based on five studies, we found a significant mean reduction in ACR, also positively related to a decrease in BP (data not shown). This could not only be explained by lower systemic arterial pressure, but also by a reduction in renal vascular resistance caused by inhibition of the renin-angiotensin-aldosterone system and the The coefficient (95% CI) represents the mean change in eGFR when the independent variable (left column) increases by 1 unit. Change in SBP and change in antihypertensive drugs are calculated as follow-up minus baseline. One unit increase for these variables means 1 mmHg higher SBP or one drug more prescribed during follow-up compared with baseline. With respect to risk of bias, the displayed risk level is compared with the other two risk levels (reference). SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; DM, diabetes mellitus.
sympathetic nervous system, as expected from treatment with RDN [26, 44] . For the present analysis we build on a previously performed meta-analysis by Howard et al. [11] . In this previous study the authors were interested in the effects of three sources of bias on results in RDN studies: regression to the mean, asymmetrical data handling and non-denervation effect (external effect). Regression to the mean is unlikely to have influenced our effect estimate even though most studies excluded patients with an eGFR 45 mL/min/1.73 m 2 . The pooled mean eGFR (75.6 6 23.0 mL/min/1.73 m 2 ) is far higher than the eGFR threshold for inclusion, and baseline eGFR was not related to the change in renal function after RDN. Also, the second cause of bias is not applicable to our set of included studies since renal function is determined at the laboratory and is therefore blinded to patients and physicians. The third source of bias (external effect) is difficult to rule out. Given our finding that eGFR does not significantly change, and assuming that RDN is harmful, external effects (e.g. lifestyle improvements) could lead to an amelioration of eGFR over time. Furthermore, results of our risk of bias assessment showed that less than one-third of cohorts are considered to have a high risk of bias. The risk of bias, as assessed in this study, was not related to change in eGFR.
The most important limitation of this meta-analysis is that the natural change in eGFR in these populations is unknown since a comparison with control cohorts is lacking. It is likely that the natural course of eGFR in these patients is declining or stable. Since we have observed no appreciable effect on eGFR, this lack of a control group is of minor importance with respect to demonstrating safety. However, any other observed effects, such as the decrease in ACR, cannot be attributed to RDN with certainty. In the previously performed meta-analysis on RCTs, a significant reduction in eGFR after 6 months in the control cohorts was shown [À2.30 mL/min/1.73 m 2 (95% CI À4.14 to À0.45], P ¼ 0.02], but there was no significant difference between the RDN and control arms [10] .
In conclusion, our systematic review and subsequent metaanalyses on change in renal function show that there are no relevant adverse effects of catheter-based RDN on renal function after a mean follow-up of 9.1 6 7.0 months. Results of an additional qualitative analysis are in line with this conclusion.
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